CLRB

Cellectar Biosciences Inc

• TipRanks·6d ago

  Cellectar Biosciences Bets on Iopofosine Breakthrough

• Benzinga·6d ago

  Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling Stockholders

• TipRanks·6d ago

  Cellectar Biosciences files to sell 51.21M shares of common stock for holders

• Reuters·6d ago

  CELLECTAR BIOSCIENCES INC - FILES FOR OFFERING OF UP TO 51.2 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING

• TipRanks·05/18 22:01

  Cellectar Biosciences Announces Board Changes and New Director

• PUBT·05/18 21:02

  Cellectar BioSciences announces annual shareholder meeting notice

• PUBT·05/18 20:17

  Cellectar Biosciences appoints Nantahala analyst Andrew Gu to board

• Dow Jones·05/15 19:41

  Cellectar Biosciences Coverage Assumed by Ladenburg Thalmann at Buy

• Dow Jones·05/15 19:41

  Cellectar Biosciences Price Target Announced at $10.00/Share by Ladenburg Thalmann

• Benzinga·05/15 19:31

  Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

• TipRanks·05/15 15:14

  Cellectar Biosciences assumed with a Buy at Ladenburg

• TipRanks·05/15 00:21

  Cellectar Biosciences Signals Pivotal Turn in Earnings Call

• Seeking Alpha·05/14 15:52

  Cellectar plans Phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027

• Benzinga·05/14 12:59

  Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call

• TipRanks·05/14 12:04

  Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)